Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A

Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions

(2018) Niken M. Mahaweni et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment

(2018) Niken M. Mahaweni et al.   Frontiers in Immunology

Natural Killer Cells: Angels and Devils for Immunotherapy

(2017) Beatriz Martín-Antonio et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput Sequencing

(2016) Paul J. Norman et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

(2016) M. Carlsten et al.   CLINICAL CANCER RESEARCH

Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1

(2016) Claudia Alicata et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment

(2016) Milena Iwaszko et al.   JOINT BONE SPINE

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

(2016) M Ilander et al.   LEUKEMIA

Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control

(2016) Megan M. Tu et al.   Frontiers in Immunology

Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia

(2016) Emily M. McWilliams et al.   OncoImmunology

Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A

(2015) Subhashis Sarkar et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

(2015) D. M. Benson et al.   CLINICAL CANCER RESEARCH

KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells

(2015) Malcolm J. W. Sim et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

(2015) L. Ruggeri et al.   HAEMATOLOGICA

The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch

(2015) Alexander A. Celik et al.   IMMUNOGENETICS

Practical NK cell phenotyping and variability in healthy adults

(2015) Laura S. Angelo et al.   IMMUNOLOGIC RESEARCH

Human KIR repertoires: shaped by genetic diversity and evolution

(2015) Angela R. Manser et al.   IMMUNOLOGICAL REVIEWS

Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

(2015) Susann Szmania et al.   JOURNAL OF IMMUNOTHERAPY

Peptide-induced HLA-E expression in human PBMCs is dependent on peptide sequence and the HLA-E genotype

(2015) N. Lauterbach et al.   TISSUE ANTIGENS

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

(2015) Guang Yang et al.   Oncotarget

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

(2015) L. Ruggeri et al.   HAEMATOLOGICA

HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response—Implications on HSCT Outcome

(2015) Thomas Kraemer et al.   Stem Cells International

Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity

(2015) Carin I. M. Dahlberg et al.   Frontiers in Immunology

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

(2015) U. Koehl et al.   OncoImmunology

Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism

(2014) Minjie Gao et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

(2014) I. S. Nijhof et al.   HAEMATOLOGICA

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

(2014) N. Korde et al.   HAEMATOLOGICA

Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype

(2014) C. Fauriat et al.   JOURNAL OF IMMUNOLOGY

Clinical and immunological significance of HLA-E in stem cell transplantation and cancer

(2014) L. Wieten et al.   TISSUE ANTIGENS

Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation

(2013) Ying-Jun Chang et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

HLA-F and MHC Class I Open Conformers Are Ligands for NK Cell Ig-like Receptors

(2013) J. P. Goodridge et al.   JOURNAL OF IMMUNOLOGY

KIR and KIR ligand polymorphism: a new area for clinical applications?

(2013) M. Falco et al.   TISSUE ANTIGENS

Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor

(2012) Mirna Balsamo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Mutation at Positively Selected Positions in the Binding Site for HLA-C Shows That KIR2DL1 Is a More Refined but Less Adaptable NK Cell Receptor Than KIR2DL3

(2012) H. G. Hilton et al.   JOURNAL OF IMMUNOLOGY

Clinical Significance of the HLA-E and CD94/NKG2 Interaction

(2011) Milena Iwaszko et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I

(2011) Xiaosong Wu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma

(2010) I. H. Gabriel et al.   BLOOD

NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation

(2010) P. Haas et al.   BLOOD

NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation

(2010) A. T. Bjorklund et al.   BLOOD

KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression

(2009) S. Andersson et al.   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells

(2009) Mónica Bernal et al.   HUMAN IMMUNOLOGY

The extensive polymorphism of KIR genes

(2009) Derek Middleton et al.   IMMUNOLOGY

KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C

(2009) Thorsten Graef et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1

(2008) M. Stern et al.   BLOOD

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

(2008) Jumei Shi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Inhibitory NKG2A and activating NKG2D and NKG2C natural killer cell receptor genes: susceptibility for rheumatoid arthritis

(2008) K. S. Park et al.   TISSUE ANTIGENS